1. Home
  2. ISPO vs RNTX Comparison

ISPO vs RNTX Comparison

Compare ISPO & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ISPO

Inspirato Incorporated

HOLD

Current Price

$4.15

Market Cap

29.9M

Sector

Finance

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.23

Market Cap

35.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ISPO
RNTX
Founded
2010
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.9M
35.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ISPO
RNTX
Price
$4.15
$1.23
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
562.2K
236.3K
Earning Date
11-04-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$247,652,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$156.55
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.19
$1.04
52 Week High
$7.17
$3.50

Technical Indicators

Market Signals
Indicator
ISPO
RNTX
Relative Strength Index (RSI) 84.14 39.35
Support Level $4.14 $1.28
Resistance Level $4.20 $1.47
Average True Range (ATR) 0.04 0.11
MACD 0.12 -0.02
Stochastic Oscillator 97.22 8.33

Price Performance

Historical Comparison
ISPO
RNTX

About ISPO Inspirato Incorporated

Inspirato Inc is a private, luxury hospitality club that provides its members with access to an exclusive portfolio of high-end vacation homes, luxury hotels, and curated travel experiences worldwide. The club offers personalized service, dedicated trip planning, and seamless access to exceptional properties through its innovative model designed to ensure the service, certainty and value that discerning customers demand. The Inspirato portfolio of curated luxury vacation options includes approximately 350 private luxury vacation homes and accommodations at over 220 luxury hotel and resort partners in over 180 destinations around the world.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: